Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Melphalan Sensitivity in Multiple Myeloma
NCT05013437Phase 1Withdrawn
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan in multiple myeloma (MM). Primary endpoint: Residual myeloma cell number measured by NGS at Day 15. Planned start Sep 2023; status: withdrawn.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05013437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013437.